Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.25
GLAXF's Cash-to-Debt is ranked lower than
81% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. GLAXF: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
GLAXF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.6 Max: N/A
Current: 0.25
Equity-to-Asset 0.03
GLAXF's Equity-to-Asset is ranked lower than
97% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. GLAXF: 0.03 )
Ranked among companies with meaningful Equity-to-Asset only.
GLAXF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0  Med: 0.25 Max: 0.67
Current: 0.03
0
0.67
Interest Coverage 5.03
GLAXF's Interest Coverage is ranked lower than
81% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. GLAXF: 5.03 )
Ranked among companies with meaningful Interest Coverage only.
GLAXF' s Interest Coverage Range Over the Past 10 Years
Min: 3.71  Med: 9.74 Max: 17.51
Current: 5.03
3.71
17.51
Piotroski F-Score: 7
Altman Z-Score: 1.40
Beneish M-Score: -2.81
WACC vs ROIC
7.69%
13.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 12.37
GLAXF's Operating Margin % is ranked higher than
65% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. GLAXF: 12.37 )
Ranked among companies with meaningful Operating Margin % only.
GLAXF' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 27.93 Max: 43.15
Current: 12.37
9.32
43.15
Net Margin % 5.77
GLAXF's Net Margin % is ranked lower than
52% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. GLAXF: 5.77 )
Ranked among companies with meaningful Net Margin % only.
GLAXF' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 18.96 Max: 35.2
Current: 5.77
3.27
35.2
ROE % 131.80
GLAXF's ROE % is ranked higher than
99% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. GLAXF: 131.80 )
Ranked among companies with meaningful ROE % only.
GLAXF' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 58.26 Max: 179.63
Current: 131.8
17.3
179.63
ROA % 2.90
GLAXF's ROA % is ranked lower than
54% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. GLAXF: 2.90 )
Ranked among companies with meaningful ROA % only.
GLAXF' s ROA % Range Over the Past 10 Years
Min: 1.62  Med: 12.76 Max: 18.45
Current: 2.9
1.62
18.45
ROC (Joel Greenblatt) % 34.24
GLAXF's ROC (Joel Greenblatt) % is ranked higher than
75% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.97 vs. GLAXF: 34.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GLAXF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.79  Med: 83.7 Max: 120.14
Current: 34.24
25.79
120.14
3-Year Revenue Growth Rate 1.80
GLAXF's 3-Year Revenue Growth Rate is ranked lower than
62% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. GLAXF: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GLAXF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 4.8 Max: 18.9
Current: 1.8
-7.7
18.9
3-Year EBITDA Growth Rate -20.50
GLAXF's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. GLAXF: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GLAXF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: 7.9 Max: 21.7
Current: -20.5
-20.5
21.7
3-Year EPS without NRI Growth Rate -44.80
GLAXF's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. GLAXF: -44.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GLAXF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 7.4 Max: 51.3
Current: -44.8
-44.8
51.3
GuruFocus has detected 5 Warning Signs with GlaxoSmithKline PLC $GLAXF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GLAXF's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, OTCPK:BAYRY, NYSE:LLY, NYSE:BMY, NYSE:SNY, NYSE:AZN, NYSE:MRK, OTCPK:ALPMY, OTCPK:OTSKF, NYSE:NVS, OTCPK:CHGCF, OTCPK:DSNKY, NYSE:PFE, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, NAS:HCM, NAS:GWPH » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GSK.USA,
Headquarter Location:UK
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across multiple therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Top Ranked Articles about GlaxoSmithKline PLC

GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting
Kahn Brothers Buys BlackBerry, Novartis, Assured Guaranty Guru's largest 1st-quarter purchases
Irving Kahn, along with brothers Alan and Thomas, founded Kahn Brothers (Trades, Portfolio) in 1978. During the first quarter the guru bought shares in the following stocks: Read more...
Pernix: An Investor's Rationale to Staying Long The stock has fallen a bit, but there's a good reason investors are staying long
I am letting you know from the beginning, I am long Pernix Therapeutics Holdings Inc. (NASDAQ:PTX). While I may have gotten to the point where I play hide-and-seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I am not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutiae and get to the nitty gritty of the issue at hand. As such, despite Pernix's current issues, I still see significant upside value. Read more...
Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Guru releases quarterly portfolio
Jeff Auxier (Trades, Portfolio) is the founder of Auxier Asset Management. His portfolio consists of 152 stocks with a total value of $460 million. During the fourth quarter of 2016, the guru sold shares in the following stocks: Read more...
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Investors are concerned about the company's lack of a plan for the future
Gilead Sciences Inc. (NASDAQ:GILD) delivered a poor performance last year. The stock lost over 24% in 2016, caused by a drop in sales of products that treat hepatitis C. According to Ben Levinsohn in a Barron's article, the decline was also attributed to the company’s lack of a plan for the future. Read more...
GlaxoSmithKline, Vodafone Hit 3-Year Low Prices 4 stocks that present opportunities to buy
GlaxoSmithKline PLC (NYSE:GSK), Diageo PLC (NYSE:DEO), Vodafone Group PLC (NASDAQ:VOD) and National Grid PLC (NYSE:NGG) have reached their three-year low prices. Read more...
Jeff Auxier Curbs Multiple Positions in 3rd Quarter Guru releases quarterly portfolio
Jeff Auxier (Trades, Portfolio) manages the  Auxier Focus Fund.The guru made the following reductions during the third quarter: Read more...
Kahn Brothers Adds to 4 Holdings in 3rd Quarter Largest acquisition is in GlaxoSmithKline
Kahn Brothers (Trades, Portfolio) added to four holdings in its portfolio in the third quarter. Read more...
Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter Nearly half of transactions involve financial services companies
Tweedy Browne (Trades, Portfolio) made five modest additions to holdings in its portfolio and two reductions that were more substantial during the third quarter. Read more...
Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...

Ratios

vs
industry
vs
history
PE Ratio 52.03
GLAXF's PE Ratio is ranked lower than
77% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.12 vs. GLAXF: 52.03 )
Ranked among companies with meaningful PE Ratio only.
GLAXF' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 14.72 Max: 99999999.99
Current: 52.03
6.35
99999999.99
Forward PE Ratio 15.50
GLAXF's Forward PE Ratio is ranked higher than
68% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.73 vs. GLAXF: 15.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 52.03
GLAXF's PE Ratio without NRI is ranked lower than
77% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.32 vs. GLAXF: 52.03 )
Ranked among companies with meaningful PE Ratio without NRI only.
GLAXF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.38  Med: 14.65 Max: 284.83
Current: 52.03
6.38
284.83
Price-to-Owner-Earnings 16.66
GLAXF's Price-to-Owner-Earnings is ranked higher than
79% of the 305 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.72 vs. GLAXF: 16.66 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GLAXF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.81  Med: 15.53 Max: 125.21
Current: 16.66
4.81
125.21
PB Ratio 50.70
GLAXF's PB Ratio is ranked lower than
98% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. GLAXF: 50.70 )
Ranked among companies with meaningful PB Ratio only.
GLAXF' s PB Ratio Range Over the Past 10 Years
Min: 5.48  Med: 9.35 Max: 610.36
Current: 50.7
5.48
610.36
PS Ratio 2.99
GLAXF's PS Ratio is ranked higher than
52% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. GLAXF: 2.99 )
Ranked among companies with meaningful PS Ratio only.
GLAXF' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.78 Max: 3.84
Current: 2.99
1.94
3.84
Price-to-Free-Cash-Flow 17.46
GLAXF's Price-to-Free-Cash-Flow is ranked higher than
67% of the 210 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.65 vs. GLAXF: 17.46 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GLAXF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 16.67 Max: 136.91
Current: 17.46
8.24
136.91
Price-to-Operating-Cash-Flow 12.19
GLAXF's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 284 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.79 vs. GLAXF: 12.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GLAXF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 11.83 Max: 27.46
Current: 12.19
6.62
27.46
EV-to-EBIT 28.72
GLAXF's EV-to-EBIT is ranked lower than
66% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. GLAXF: 28.72 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.7 Max: 72.6
Current: 28.72
6.3
72.6
EV-to-EBITDA 20.17
GLAXF's EV-to-EBITDA is ranked lower than
56% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.60 vs. GLAXF: 20.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.2 Max: 35.2
Current: 20.17
5.6
35.2
Shiller PE Ratio 18.81
GLAXF's Shiller PE Ratio is ranked higher than
85% of the 196 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.28 vs. GLAXF: 18.81 )
Ranked among companies with meaningful Shiller PE Ratio only.
GLAXF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.71  Med: 15.16 Max: 21.1
Current: 18.81
11.71
21.1
Current Ratio 0.89
GLAXF's Current Ratio is ranked lower than
92% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. GLAXF: 0.89 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.3 Max: 2.64
Current: 0.89
0.88
2.64
Quick Ratio 0.61
GLAXF's Quick Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. GLAXF: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.01 Max: 2.24
Current: 0.61
0.61
2.24
Days Inventory 200.23
GLAXF's Days Inventory is ranked lower than
82% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.03 vs. GLAXF: 200.23 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 188.56 Max: 202.64
Current: 200.23
167.28
202.64
Days Sales Outstanding 81.07
GLAXF's Days Sales Outstanding is ranked lower than
55% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. GLAXF: 81.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.8 Max: 93.9
Current: 81.07
54.62
93.9
Days Payable 135.73
GLAXF's Days Payable is ranked higher than
80% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.27 vs. GLAXF: 135.73 )
Ranked among companies with meaningful Days Payable only.
GLAXF' s Days Payable Range Over the Past 10 Years
Min: 98.94  Med: 133.85 Max: 345.65
Current: 135.73
98.94
345.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.48
GLAXF's Dividend Yield % is ranked higher than
95% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. GLAXF: 4.48 )
Ranked among companies with meaningful Dividend Yield % only.
GLAXF' s Dividend Yield % Range Over the Past 10 Years
Min: 2.92  Med: 5.12 Max: 6.24
Current: 4.48
2.92
6.24
Dividend Payout Ratio 2.35
GLAXF's Dividend Payout Ratio is ranked lower than
97% of the 404 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. GLAXF: 2.35 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GLAXF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.75 Max: 4.3
Current: 2.35
0.46
4.3
3-Year Dividend Growth Rate -1.30
GLAXF's 3-Year Dividend Growth Rate is ranked lower than
66% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. GLAXF: -1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GLAXF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 62.4
Current: -1.3
0
62.4
Forward Dividend Yield % 4.75
GLAXF's Forward Dividend Yield % is ranked higher than
94% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. GLAXF: 4.75 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.66
GLAXF's 5-Year Yield-on-Cost % is ranked higher than
86% of the 808 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. GLAXF: 4.66 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GLAXF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.04  Med: 5.33 Max: 6.49
Current: 4.66
3.04
6.49
3-Year Average Share Buyback Ratio -0.40
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. GLAXF: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.7  Med: -0.5 Max: 4.7
Current: -0.4
-26.7
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.45
GLAXF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
51% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. GLAXF: 2.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GLAXF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.96  Med: 1.94 Max: 70.18
Current: 2.45
0.96
70.18
Price-to-Median-PS-Value 1.08
GLAXF's Price-to-Median-PS-Value is ranked higher than
55% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. GLAXF: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLAXF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 1.18 Max: 3.35
Current: 1.08
0.62
3.35
Earnings Yield (Greenblatt) % 3.49
GLAXF's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.98 vs. GLAXF: 3.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLAXF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 9.4 Max: 15.8
Current: 3.49
1.4
15.8
Forward Rate of Return (Yacktman) % -8.86
GLAXF's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.09 vs. GLAXF: -8.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GLAXF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.9  Med: 8.8 Max: 18.2
Current: -8.86
-8.9
18.2

More Statistics

Revenue (TTM) (Mil) $37,775.76
EPS (TTM) $ 0.42
Beta1.22
Short Percentage of Float0.00%
52-Week Range $18.16 - 22.98
Shares Outstanding (Mil)4,918.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 38,087 39,236 40,312
EPS ($) 1.39 1.42 1.56
EPS without NRI ($) 1.39 1.42 1.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.49%
Dividends per Share ($) 1.03 1.03 1.03
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
LendingClub Closes First Self-Sponsored Securitization to Expand Investor Access Jun 22 2017 
Penn West Announces Webcast Details for the Presentation at the Annual and Special Meeting on June 2 Jun 22 2017 
XL Group Ltd Announces Pricing of EUR Subordinated Notes Jun 22 2017 
BNY Mellon Announces Results of Its 2017 Annual Stress Test Jun 22 2017 
Huntington Bancshares Releases Results Of 2017 Dodd-Frank Act Company-Run Capital Stress Test Jun 22 2017 
Barrick and NOVAGOLD to Advance Ongoing Donlin Gold Project Optimization With Approved $8-Million Dr Jun 22 2017 
Dentsply Sirona Declares Quarterly Cash Dividend Jun 22 2017 
Haemonetics Announces Formation of Scientific Advisory Council Jun 22 2017 
Broadridge Named "Service Provider of the Year" and Charlie Marchesani named "Ops Business Person of Jun 22 2017 
Evolent Health, Inc. Announces Launch of Secondary Public Offering of Class A Common Stock Jun 22 2017 

More From Other Websites
GSK's new CEO aims to divest sports nutrition brand: sources Jun 22 2017
Glaxo's (GSK) Shingles Candidate Phase III Data Positive Jun 22 2017
Early movers: ORCL, HAIN, ACN, SCS, ATUS, NVS, GSK & more Jun 22 2017
GSK wins $235 million from Teva in Coreg patent trial Jun 21 2017
GSK's new pharma head to join in September after AstraZeneca tussle Jun 19 2017
GlaxoSmithKline's Benlysta Positive in Continuation Trial Jun 19 2017
5 Answers to Questions Gilead Sciences' Investors Probably Have Jun 18 2017
Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now? Jun 16 2017
Why GlaxoSmithKline Stock Had a Breakout May Jun 09 2017
2 High-Yield Dividend Stocks That Might Be Incredible Bargains Right Now Jun 07 2017
2 giant drugmakers are racing to make a breakthrough in treating HIV, and there's $22 billion on the... Jun 06 2017
GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment Jun 02 2017
Deed records reveal sale price, billionaire buyer of GSK’s RTP campus Jun 01 2017
GlaxoSmithKline’s Vaccines Segment in 1Q17 Jun 01 2017
GlaxoSmithKline’s Segment Performances in 1Q17 May 31 2017
How GlaxoSmithKline’s Valuation Changed after 1Q17 May 31 2017
GlaxoSmithKline Surges to New Highs May 31 2017
European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data May 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}